According to this report, the global sexually transmitted diseases testing market reached a value of around USD 96.9 billion in 2022. Aided by the increasing prevalence of sexually transmitted diseases worldwide and the growing awareness about the importance of early diagnosis and treatment, the market is projected to further grow at a CAGR of 5.80% between 2023 and 2028 to reach a value of USD 128.45 billion by 2028.
Sexually transmitted diseases, such as HIV/AIDS, syphilis, gonorrhoea, and chlamydia, among others, represent a significant public health challenge worldwide. Early detection and treatment are crucial to preventing severe health complications and controlling the spread of these diseases. STD testing is, therefore, an essential part of preventive healthcare and is used in various settings, from public health clinics and hospitals to private practices and home-based testing.
The increasing prevalence of STDs is the primary driver of the global sexually transmitted diseases testing market growth. According to the World Health Organisation, over 1 million sexually transmitted infections are acquired every day worldwide. These alarming statistics underline the urgent need for accessible and accurate STD testing services.
In parallel, there is growing awareness of the importance of early diagnosis and treatment of STDs. This increased awareness is largely due to extensive public health campaigns and education initiatives that highlight the importance of regular testing, particularly for high-risk populations.
Furthermore, the sexually transmitted diseases testing market is witnessing the rapid development and commercialisation of innovative diagnostic technologies, such as rapid point-of-care tests and advanced molecular diagnostic platforms. These innovations enable more accurate, faster, and more convenient testing, which is key to increasing testing rates and controlling the spread of STDs.
In addition to these factors, the global push towards universal health coverage, including sexual and reproductive health services, is expected to significantly increase access to STD testing services, thus contributing to the sexually transmitted diseases testing market expansion.
The ongoing advancements in diagnostic technologies, coupled with increasing public health efforts to increase access to testing and reduce stigma, are expected to continue driving the sexually transmitted diseases testing market growth over the forecast period.
The high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in this market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.
Don't miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation's future success by acquiring one of these reports today.
The analyst always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
Sexually transmitted diseases, such as HIV/AIDS, syphilis, gonorrhoea, and chlamydia, among others, represent a significant public health challenge worldwide. Early detection and treatment are crucial to preventing severe health complications and controlling the spread of these diseases. STD testing is, therefore, an essential part of preventive healthcare and is used in various settings, from public health clinics and hospitals to private practices and home-based testing.
The increasing prevalence of STDs is the primary driver of the global sexually transmitted diseases testing market growth. According to the World Health Organisation, over 1 million sexually transmitted infections are acquired every day worldwide. These alarming statistics underline the urgent need for accessible and accurate STD testing services.
In parallel, there is growing awareness of the importance of early diagnosis and treatment of STDs. This increased awareness is largely due to extensive public health campaigns and education initiatives that highlight the importance of regular testing, particularly for high-risk populations.
Furthermore, the sexually transmitted diseases testing market is witnessing the rapid development and commercialisation of innovative diagnostic technologies, such as rapid point-of-care tests and advanced molecular diagnostic platforms. These innovations enable more accurate, faster, and more convenient testing, which is key to increasing testing rates and controlling the spread of STDs.
In addition to these factors, the global push towards universal health coverage, including sexual and reproductive health services, is expected to significantly increase access to STD testing services, thus contributing to the sexually transmitted diseases testing market expansion.
The ongoing advancements in diagnostic technologies, coupled with increasing public health efforts to increase access to testing and reduce stigma, are expected to continue driving the sexually transmitted diseases testing market growth over the forecast period.
Market Segmentation
The market can be divided based on disease type, device type, and region.Market Breakup by Disease Type
- Chlamydia
- Gonorrhoea
- Herpes Simplex Virus
- Syphilis
- Human Papillomavirus (HPV)
- Others
Market Breakup by Device Type
- Laboratory Devices
- Thermal Cyclers- PCR
- Lateral Flow Readers
- Flow Cytometers
- Differential Light Scattering Machines
- Absorbance Microplate Reader
- Others
- Point of Care (POC) Devices
- Phone Chips (Microfluidics and ICT)
- Portable/Bench Top/Rapid Diagnostic
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Competitive Landscape
This report looks into the market shares, plant turnarounds, capacities, investments, and acquisitions and mergers, among other major developments, of the global sexually transmitted diseases testing companies. Some of the major key players explored in this report are as follows:- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Quidel Corporation
- Hologic, Inc.
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A
- QIAGEN GmbH
- Becton, Dickinson and Company
- Others
About the Analyst
Acquire unparalleled access to critical industry insights with our comprehensive market research reports, meticulously prepared by a team of seasoned experts. These reports are designed to equip decision-makers with an in-depth understanding of prevailing market trends, competitive landscapes, and growth opportunities.The high-quality, data-driven analyses provide the essential framework for organisations seeking to make informed and strategic decisions in an increasingly complex and rapidly evolving business environment. By investing in this market research reports, you can ensure your organisation remains agile, proactive, and poised for success in today's competitive market.
Don't miss the opportunity to elevate your business intelligence and fortify your strategic planning. Secure your organisation's future success by acquiring one of these reports today.
The analyst always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
Table of Contents
1 Preface2 Report Coverage - Key Segmentation and Scope4 Key Assumptions7 Opportunities and Challenges in the Market16 Key Trends and Developments in the Market
3 Report Description
5 Executive Summary
6 Market Snapshot
8 Global Sexually Transmitted Diseases Testing Market Analysis
9 North America Sexually Transmitted Diseases Testing Market Analysis
10 Europe Sexually Transmitted Diseases Testing Market Analysis
11 Asia Pacific Sexually Transmitted Diseases Testing Market Analysis
12 Latin America Sexually Transmitted Diseases Testing Market Analysis
13 Middle East and Africa Sexually Transmitted Diseases Testing Market Analysis
14 Market Dynamics
15 Competitive Landscape
List of Key Figures and Tables
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Quidel Corporation
- Hologic Inc.
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A
- QIAGEN GmbH
- Becton
- Dickinson and Company
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 163 |
Published | October 2023 |
Forecast Period | 2023 - 2028 |
Estimated Market Value ( USD | $ 96.9 Billion |
Forecasted Market Value ( USD | $ 128.45 Billion |
Compound Annual Growth Rate | 5.8% |
Regions Covered | Global |
No. of Companies Mentioned | 11 |